

University of Rhode Island

DigitalCommons@URI

Institute for Immunology and Informatics
Faculty Publications

Institute for Immunology and Informatics
(iCubed)

2014

Immune Camouflage: Relevance to Vaccine Design and Human Immunology

Anne S. De Groot

University of Rhode Island, annied@uri.edu

Leonard Moise

University of Rhode Island

Rui Liu

Andres H. Gutierrez

Ryan Tassone

See next page for additional authors

Follow this and additional works at: https://digitalcommons.uri.edu/immunology_facpubs

Citation/Publisher Attribution

De Groot, A. S., Moise, L., Liu, R., Gutierrez A. H., Tassone, R., Bailey-Kellog, C., & Martin, W. (2014).

Immune Camouflage: Relevance to Vaccine Design to Human Immunology. *Human Vaccines & Immunotherapeutics*, 10(12), 3570-3575.

Available at: <http://www.tandfonline.com/doi/full/10.4161/hv.36134>

This Article is brought to you by the University of Rhode Island. It has been accepted for inclusion in Institute for Immunology and Informatics Faculty Publications by an authorized administrator of DigitalCommons@URI. For more information, please contact digitalcommons-group@uri.edu. For permission to reuse copyrighted content, contact the author directly.

Immune Camouflage: Relevance to Vaccine Design and Human Immunology

Authors

Anne S. De Groot, Leonard Moise, Rui Liu, Andres H. Gutierrez, Ryan Tassone, Chris Bailey-Kellogg, and William Martin

The University of Rhode Island Faculty have made this article openly available.
Please let us know how Open Access to this research benefits you.

This is a pre-publication author manuscript of the final, published article.

Terms of Use

This article is made available under the terms and conditions applicable towards Open Access Policy Articles, as set forth in our [Terms of Use](#).

See discussions, stats, and author profiles for this publication at: <http://www.researchgate.net/publication/265165140>

Immune Camouflage: Relevance to Vaccine Design and Human Immunology Leonard Moise, Rui Liu, Andres H Gutierrez, Ryan Tassone, Chris Bailey-Kellogg, Bill Martin, Anne S De Groot* ht...

ARTICLE *in* HUMAN VACCINES · DECEMBER 2014

Impact Factor: 3.64

READS

50

1 AUTHOR:



Anne S De Groot

EpiVax, Inc.

213 PUBLICATIONS 3,109 CITATIONS

SEE PROFILE

1 **Immune Camouflage: Relevance to Vaccine Design and Human Immunology**

2

3 **Running title: Emerging Pathogen Adopts Camouflage Strategy**

4

5 Anne S. De Groot^{1,2,*}, Lenny Moise¹, Rui Liu², Andres H. Gutierrez²,

6 Ryan Tassone², Chris Bailey-Kellogg³, William Martin¹

7

8 ¹EpiVax, Inc., Providence, RI, USA; ²Institute for Immunology and Informatics, University of
9 Rhode Island, Providence, RI, USA; ³Dartmouth College, Hanover, NH, USA.

10

11 *Corresponding author:

12 Anne De Groot, MD, CEO/CSO EpiVax Inc., 146 Clifford St., Providence, RI 02903; Director,
13 Institute of Immunology and Informatics and Professor (Research) University of Rhode Island, 80
14 Washington St., Providence, RI 02903

15 Telephone: 401-272-2123

16 Fax: 401-272-7562

17 Email: dr.annie.degroot@gmail.com

18

19 **Conflict of interest**

20 ADG and WM are founders and majority owners of EpiVax, Inc. a biotechnology company that
21 provides access to immunoinformatics tools and to the Tregitope technology to commercial
22 clients. Due to this relationship with EpiVax, the authors acknowledge that there is a potential
23 conflict of interest inherent in the publication of this manuscript, and asserts that they made an
24 effort to reduce or eliminate that conflict where possible. In addition to his role as a faculty
25 member at Dartmouth, CBK is co-founder and CTO of Stealth Biologics, LLC, a therapeutic
26 protein design company. Dartmouth has worked with him to manage all potential conflicts of
27 interest arising from his commercial affiliation, and he likewise affirms that this paper presents
28 work free of any bias.

1 **Keywords**

2 **Treg, Tolerance, Vaccine, Biologic, Deimmunization, Tregitope, JanusMatrix, EpiMatrix**

3

4 **Abbreviations and acronyms**

5 HA: hemagglutinin; HLA: human leukocyte antigen; HCV: Hepatitis C virus; HIV: human
6 immunodeficiency virus; IAVs: influenza A viruses; nTreg: natural regulatory T cells; TCR: T cell
7 receptor; Td response: T cell-driven response; Treg: regulatory T cell; Tregitope: Treg epitope

8

9 **Abstract**

10 High strain sequence variability, interference with innate immune mechanisms, and epitope
11 deletion are all examples of strategies that pathogens have evolved to subvert host defenses. To
12 this list we would add another strategy: *immune camouflage*. Pathogens whose epitope
13 sequences are cross-conserved with multiple human proteins at the TCR-facing residues may be
14 exploiting “ignorance and tolerance”, which are mechanisms by which mature T cells avoid
15 immune responses to self-antigens. By adopting amino acid configurations that may be
16 recognized by autologous regulatory T cells, pathogens may be actively suppressing protective
17 immunity. Using the new JanusMatrix TCR-homology-mapping tool, we have identified several
18 such ‘camouflaged’ tolerizing epitopes that are present in the viral genomes of pathogens such as
19 emerging H7N9 influenza. Thus in addition to the overall low number of T helper epitopes that is
20 present in H7 hemagglutinin (as described previously, see <http://dx.doi.org/10.4161/hv.24939>), the
21 presence of such tolerizing epitopes in H7N9 could explain why, in recent vaccine trials, whole
22 H7N9-HA was poorly immunogenic and associated with low seroconversion rates (see
23 <http://dx.doi.org/10.4161/hv.28135>). In this commentary, we provide an overview of the
24 immunoinformatics process leading to the discovery of tolerizing epitopes in pathogen genomic
25 sequences, provide a brief summary of laboratory data that validates the discovery, and point the
26 way forward. Removal of viral, bacterial and parasite tolerizing epitopes may permit researchers
27 to develop more effective vaccines and immunotherapeutics in the future.

28

29

1 **Immune Camouflage: Relevance to Vaccine Design and Human Immunology**

2

3 **Learning from pathogens how to make better vaccines and biologics**

4 Just as humans have evolved immune mechanisms to combat infection, viruses, bacteria, and
5 parasites have found ways to fight back against human defenses. It appears that the emerging
6 H7N9 influenza virus is one of several viruses that have learned to evade host defenses. Immune
7 evasion strategies contribute to pathogen persistence at the population and individual level,
8 making it difficult to develop effective vaccines. Examples of pathogens for which effective
9 vaccines are lacking include herpes simplex virus (HSV), human immuno-deficiency virus (HIV),
10 respiratory syncytial virus (RSV), and cytomegalovirus (CMV) among viruses; *M. tuberculosis*, *H.*
11 *pylori*, and *S. aureus* among bacteria; and Leishmania, Trypanosoma, and Filaria species among
12 parasites. Vaccines developed against H7N9 have also proven to be poorly immunogenic, as
13 compared to those developed for the most recent pandemic (H1N1), perhaps due to immune
14 evasion strategies described previously by our group.^{1,2}

15

16 Fortunately, human beings can learn to fight back. Using advanced bioinformatics tools, we are
17 now able to search pathogen sequences for elements that enable pathogen escape from the
18 immune system and use this information to improve vaccines. The same approach may also be
19 used to improve vaccines against cancer antigens (by identifying regions of those antigens that
20 may be actively tolerizing) and to reduce the immunogenicity of biologic therapeutics (by
21 introducing or conserving tolerogenic epitopes to promote drug-specific tolerance). Our group
22 uses an integrated set of bioinformatics tools (iVAX) that have been extensively validated for
23 antigen sequence analysis and vaccine design³ to identify immunogenic signals encoded in
24 pathogen genomes; recent papers describing the use of the iVAX toolkit include applications to *H.*
25 *pylori*⁴ and Hepatitis C.⁵

26

27 One weapon that we can use to fight back against human pathogens is to design better vaccines.
28 JanusMatrix is a new tool for analyzing the genomes of pathogens that appears to be capable of

1 identifying regulatory T cell (Treg) epitopes. We described the application of this tool to the
2 emerging H7N9 avian influenza genome in this journal. Our initial immunoinformatics analysis
3 revealed two potential means by which H7N9 might evade immune response: (1) reduced
4 numbers of T helper epitopes in the H7N9 hemagglutinin (HA) protein, the primary antigen
5 against which protective antibody response is focused¹ and (2) the presence of T cell epitopes
6 highly cross-conserved with the human genome.² Subsequent reports revealed that vaccines
7 developed using H7N9-HA were indeed poorly immunogenic, as was predicted. Extremely low
8 seroconversion rates of 6% were observed.^{6,7} In contrast, the rate of seroconversion to
9 unadjuvanted monovalent pandemic H1N1 is reported to be 89%.⁸⁻¹⁰ Perhaps more importantly,
10 and related to the relative paucity of T helper epitopes, careful analysis of humoral immune
11 responses to H7N9 revealed that human antibody response to the virus was diminished and
12 delayed, and the resulting HA-specific antibodies had poor avidity compared to serological
13 responses to other influenza subtypes.¹¹

14

15 **A new mechanism of immune escape: immune camouflage**

16

17 More specifically, as will be reviewed here, the JanusMatrix tool has uncovered the ability of
18 some pathogens to introduce HLA class II sequences (over the course of their co-evolution with
19 human hosts) that are highly cross-conserved at the T cell receptor (TCR) face with the human
20 genome¹² (**Figure 1**). This is a new mechanism of subterfuge, and it is deserving of intensive
21 study, since it may explain why it has been difficult to develop effective vaccines for certain
22 pathogens using subunit (whole antigen) vaccines. Furthermore, we can leverage this information
23 by searching pathogen genomes for human homologs: these “human-like” epitopes may play an
24 important role in the regulation of immune tolerance.

25

26 Maintaining tolerance is an active and constant process that involves regulatory T cells (Tregs),
27 and reinforcement by the continued presence of antigen may be important.¹³ Circulating Tregs

1 dampen immune responses to self-epitopes displayed on antigen-presenting cells, diminishing
2 the chance of autoimmunity.

3 We believe that pathogens may use the same tolerance-inducing Tregs as a means of escaping
4 immune response. Accordingly, this commentary expands on our previous observations related to
5 emerging H7N9 in this journal by explaining how JanusMatrix can be used to identify HLA class II
6 epitopes from pathogen sequences that have identical TCR-facing residues to multiple human
7 genome epitopes.¹² We are now using JanusMatrix for large-scale analyses of viral, bacterial and
8 parasite sequences for such tolerizing, or Treg epitope (“Tregitope”) signals and validating this
9 hypothesis *in vitro* and *in vivo*. While Tregitopes and tolerizing epitopes may improve biologics,¹⁴
10 they may hinder the effectiveness of subunit vaccines¹⁵ in the clinic.

11

12 **Established immune escape mechanisms**

13

14 Although novel, viral camouflage is not the first mechanism of immune escape to be discovered.
15 There is an extensive literature on the many ways by which pathogens evade detection, some of
16 which are described briefly in the following paragraphs.

17

18 **a. Defense against innate immunity**

19 Bacteria and viruses are known to interfere with innate immune responses by producing
20 proteases that degrade host defense factors,¹⁶ secreting exact replicates of human cytokines that
21 suppress immune response,¹⁷ cleaving or evading complement activation,¹⁸ impeding phagocyte
22 recruitment,¹⁹ interfering with reactive oxygen species,²⁰ escaping neutrophil extracellular traps,²¹
23 and generating pore-forming cytolysins,²² among other mechanisms.

24

25 **b. Defense against adaptive immune response**

26 Viruses also delete T cell epitopes to evade recognition by human T cells. This process, known
27 as “deimmunization” in the biologics industry, has been observed in the course of infection by
28 RNA viruses (HIV, HCV²³⁻²⁵). Evaluations of total T cell epitope content in bacterial genomes

1 appear to confirm that deimmunization may also occur in selected bacteria.²⁶ Since viruses have
2 successfully demonstrated that T cell epitope deletion is a viable immune escape strategy,
3 deimmunization has been applied to the development of less immunogenic protein therapeutics.²⁷
4 Importantly, reduction of T cell epitopes is not limited to avoiding immune recognition; it also
5 results in reduced antibody titers and diminished antibody affinity.¹¹

6

7 **c. Treg epitopes or tolerizing epitopes**

8 In 2007, we made the surprising discovery that there were highly conserved, promiscuous T-cell
9 epitopes located in the Fc region and framework of the Fab region of IgG.²⁸ We hypothesized that
10 these were regulatory T cell epitopes, which we nicknamed Tregitopes, and later determined that
11 natural regulatory T cells (nTregs) upregulated FoxP3 following exposure to Tregitopes *in vitro*,
12 suppressed bystander immune responses, modified antigen presenting cell phenotype toward a
13 tolerogenic DC (DCreg²⁹), and that Tregitope treatment *in vivo* induced adaptive tolerance.³⁰

14

15 One question that frequently came up when we presented our new Tregitope discovery was
16 whether similar peptides were also found in pathogen genomes. However, we were not able to
17 search for pathogen Tregitopes until we developed JanusMatrix. This tool made it possible to
18 begin to search viral, bacterial, and parasite genomes for human homology at the TCR face. For
19 example, with Bailey-Kellogg and He of Dartmouth, we used JanusMatrix to scan viral genomes
20 for Tregitopes, and found that chronic or commensal viruses (“hit-and-stay”) that establish
21 persistent infection in humans are deimmunized and contain more viral Tregitopes than viruses
22 that “hit-and-run” such as Ebola, Marburg and variola.¹²

23

24 Identification of tolerizing epitopes in pathogen sequences (and development of tools for defining
25 them) has important ramifications for the design of vaccines against human pathogens,
26 particularly those that persist in humans and appear to have adopted this immune defense. The
27 evolution of this concept and a few case studies are presented in the following sections.

28

1 **Defining Pathogen “Tregitopes”?**

2

3 Cross-reactivity is an intrinsic characteristic of the TCR that is widely recognized to be critically
4 important for the development of thymus-derived T cells, autoimmunity, and heterologous
5 immunity. To define cross-conserved T cell epitopes, we use JanusMatrix, which operates in
6 conjunction with an existing T cell epitope-mapping platform (EpiMatrix)³¹ JanusMatrix harnesses
7 EpiMatrix to define HLA-binding peptides while searching for cross-conservation at the TCR face
8 in any protein sequence databases of interest (uploaded and selected by the user). We have
9 examined TCR-facing residues for conservation against a variety of human sequence databases,
10 including the complete human proteome, the plasma proteome and the human microbiome.³¹

11

12 Preliminary studies appear to corroborate the immune camouflage hypothesis. In collaboration
13 with Gregory and Losikoff, we discovered a tolerizing epitope in HCV using JanusMatrix.³¹
14 Subsequently, we discovered and described epitopes in H7N9 that have similar features³²
15 **(Figure 2)**. In the next three sections, we summarize our recent experience with JanusMatrix and
16 highlight the validation studies that have been performed. These newly defined viral Tregitopes
17 will be described briefly below.

18

19 **a. HCV**

20 Gregory and Losikoff prospectively identified highly human-like and promiscuous HCV T cell
21 epitopes that were subsequently shown to be Tregitopes in the context of chronic HCV
22 infection.³³ One particular sequence, which stimulated interferon-gamma production by T
23 lymphocytes derived from non-HCV-infected patients, induced a significant increase in functional
24 CD3+CD4+FoxP3+ Tregs among PBMCs derived from young adults who were recently infected
25 (<5 years) and remained infected with HCV (Losikoff et al. manuscript in preparation³⁴). Other,
26 less human-like HCV peptides had no effect on Treg cell expansion. Importantly, a human
27 peptide to which the HCV peptide had identical TCR-facing residues also stimulated a marked
28 increase in Tregs among PBMCs from non-infected as well as infected individuals. This suggests

1 that the HCV genome contains cross-reactive viral epitopes that can suppress Teffector cell
2 function by promoting Treg cell activity. In fact, it is already well established that HCV-induced
3 Treg activation is associated with extended chronicity of HCV infection,³⁵ but until now it has been
4 difficult to define which T cell epitopes engage human Tregs.

5

6 **b. Influenza**

7 We previously described H7N9 influenza 2013 as a “stealth” virus, capable of evading human
8 immune response.¹ In addition to the low T cell epitope content and limited conservation with
9 circulating influenza strains, tolerizing epitopes may be present in H7-HA, contributing to the low
10 immunogenicity and poor efficacy of the HA-based vaccine.² Consistent with our previous
11 analysis of viral genomes,¹² we have identified a number of T cell epitopes in H7N9 that are
12 cross-conserved with other influenza A viruses (IAVs) but also extensively cross-conserved with
13 human genome. Peptides that are extensively cross-conserved with human genome may have an
14 immuno-suppressive effect, which could explain why the development of antibodies to H7 HA
15 appears to be delayed and the antibodies have poor affinity when compared to other antibodies
16 to other HA proteins in H7N9-infected patients.¹¹ Our *in vitro* studies of cross-reactive peptides in
17 H7N9 appear to support the observations made in the case of HCV, described above.³²

18

19 **c. HIV**

20 We recently applied JanusMatrix to analyzing the HIV genome, rationalizing that RNA viruses
21 may be alike in their propensity to adopt immune camouflage as a means of escaping immune
22 response. To our surprise, several epitopes contained in the Env protein appear to be highly
23 cross-conserved with the human genome. One such epitope is depicted using Cytoscape to
24 describe its connectedness with other epitopes in the human genome, **Figure 3**. We are currently
25 evaluating this epitope, and other epitopes like it, to determine whether these epitopes may
26 contribute to immune camouflage, in HIV infection.

27

1 Relevance to Vaccine design

2

3 Conservation with the human genome may be a means by which viruses escape human immune
4 response. Better classification of viral epitopes as either effector or regulatory will improve the
5 design of vaccines against pathogens that adopt immune camouflage. Modification of vaccine
6 immunogens to epitopes that drive viral-specific T cell responses may also improve the efficacy of
7 these vaccines. Alternatively, one might develop epitope-driven subunit vaccines, either as whole
8 antigen vaccines, using a structure-based approach, or alternatively, as platform-neutral epitope-
9 based vaccines that do not contain tolerizing epitopes or Tregitopes. Such vaccines may have
10 major advantages over conventional approaches, as they simultaneously account for viral and
11 human diversity for broad reactivity and drive protective viral-specific T cell responses. For
12 instance, the low immunogenicity of H7N9 might be overcome by introducing into the vaccine T
13 cell epitopes cross-conserved with seasonal influenza A strains and removing vaccine epitopes
14 cross-conserved with human proteins, which may promote down-regulation of protective
15 inflammatory responses.

16

17 Relevance to biologics design

18 Whereas immunogenicity is considered to be a positive attribute for vaccines, immunogenicity
19 that occurs in the course of treatment with biologic therapies is a topic of some concern to
20 biologics developers. While there are many factors that contribute to protein immunogenicity, T
21 cell-driven (Td) responses appear to play a critical role in the development of antibody responses
22 to biologic therapeutics. A range of methodologies to predict and mitigate Td immune responses
23 to protein drugs has been developed. Perhaps integrating Tregitopes into protein therapeutics will
24 reduce their immunogenicity.¹⁴ We also plan to scan protein therapeutics for pre-existing
25 Tregitopes; our deimmunization programs would leave Tregitopes intact while removing other,
26 more immunogenic T cell epitopes.

27

1 **Conclusion**

2

3 The implication of the studies emerging from the exploration of the “two-faced” T cell epitope with
4 the JanusMatrix tool is that TCR cross-reactivity at the level of the human genome is potentially
5 linked to a Treg phenotype of human T cell responses to pathogens. The implications for vaccine
6 developers should be clear: remove such epitopes from vaccine antigens. The implications for
7 biologics developers may be more nuanced but are equally important – prioritization of T cell
8 epitopes for removal may depend on the degree of cross-conservation with self, even if the
9 protein is autologous in origin.

10

11 In addition, TCR cross-reactivity may play a role in autoimmune disease through a concept
12 known as molecular mimicry.³⁶ Applications of JanusMatrix may be relevant, therefore, in the
13 context of autoimmune diseases following vaccination, such as Guillain-Barre syndrome or
14 Narcolepsy.³⁷⁻³⁹

15

16 Finally, pathogen subterfuge may teach us something about our own immune system. What is the
17 role of human peptide epitopes that are themselves cross-reactive with other human sequences?
18 Are these Tregitopes serving an important purpose, reinforcing tolerance to proteins that are
19 critically important for human survival? Pathogens may have exploited an immune tolerance
20 mechanism that we were completely unaware of until now.

21

22 **Acknowledgements**

23 The assistance of Genevieve S. De Groot with the figures for this manuscript and Sarah Beseme
24 with the preparation of the manuscript and figures is sincerely appreciated.

25

1 References

- 1 De Groot AS, Ardito M., Terry, F. Levitz L., Ross T., Moise L., Martin B. Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design. *Hum Vaccin Immunother* 2013; 9(5):950-6.
- 2 De Groot AS, Moise L, Liu R, Gutierrez AH, Terry F, Koita OA, Ross TM, Martin W. Cross-conservation of T-cell epitopes: Now even more relevant to [H7N9] influenza vaccine design. *Hum Vaccin Immunother* 2014; 10(2):256-62.
- 3 Moise L, Cousens L, Fueyo J, De Groot AS. Harnessing the power of genomics and immunoinformatics to produce improved vaccines. *Expert Opin Drug Discov* 2011; 6(1):9-15.
- 4 Zhang S, Desrosiers J, Aponte-Pieras JR, DaSilva K, Fast LD, Terry F, Martin WD, De Groot AS, Moise L, Moss S. Human immune responses to *H. pylori* HLA Class II epitopes identified by immunoinformatic methods. *PLoS One* 2014; 9(4):e94974.
- 5 Mishra S, Losikoff PT, Self AA, Terry F, Ardito MT, Tassone R, Martin WD, De Groot AS, Gregory SH. Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells. *Vaccine* 2014; 32(26):3285-92.
- 6 Novartis announces positive clinical trial results for novel H7N9 vaccine. Media Release on Novartis Website [Internet] 2013 [cited 2014 Jul 28]; Available from: <http://www.novartis.com/newsroom/media-releases/en/2013/1743124.shtml>
- 7 Fries LF, Smith GE, Glenn GM. (NovaVax) A recombinant viruslike particle influenza A (H7N9) vaccine. *N Engl J Med* 2013; 369(26):2564-6.

-
- 8 Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, Talbot HK, Ohmit SE, Coleman LA, Lofthus G et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. *PLoS One* 2011; 6(8):e23085.
- 9 Centers for Disease Control and Prevention (CDC). Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014. *MMWR Recomm Rep* 2013; 62(RR-07):1-43.
- 10 Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: A quantitative review. *Vaccine* 2006; 24(8):1159-1169.
- 11 Guo L, Zhang X, Ren L, Yu X, Chen L, Zhou H, Gao X, Teng Z, Li J, Hu J et al. Human antibody responses to avian influenza A(H7N9) virus, 2013. *Emerg Infect Dis* 2014; 20(2):192-200.
- 12 He L, De Groot AS, Gutierrez AH, Martin WD, Moise L, Bailey-Kellogg C. Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. *BMC Bioinformatics* 2014; 15(Suppl 4):S1.
- 13 Rosenblum MD, Gratz IK, Paw JS, Lee K, Marshak-Rothstein A, Abbas AK. Response to self antigen imprints regulatory memory in tissues. *Nature* 2011; 480(7378):538-42.
- 14 De Groot AS, Terry F, Cousens L, Martin W. Beyond Humanization and De-immunization: Tolerization as a Method for Reducing the Immunogenicity of Biologics. *Expert Rev Clin Pharmacol* 2013; 6(6):651-62.

-
- 15 Wang HY, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4⁺ regulatory T cells and their ligands: implications for immunotherapy. *Immunity* 2004; 20(1):107-18.
- 16 Dubin G, Koziel J, Pyrc K, Wladyka B, Potempa J. Bacterial proteases in disease - role in intracellular survival, evasion of coagulation/ fibrinolysis innate defenses, toxicoses and viral infections. *Curr Pharm Des* 2013; 19(6):1090-113.
- 17 Sin SH, Dittmer DP. Cytokine homologs of human gamma herpes viruses. *J Interferon Cytokine Res* 2012; 32(2):53-9.
- 18 Jongerius I, Ram S, Rooijackers S. Bacterial complement escape. *Adv Exp Med Biol* 2009; 666:32-48.
- 19 de Haas CJ, Veldkamp KE, Peschel A, Weerkamp F, Van Wamel WJ, Heezius EC, Poppelier MJ, Van Kessel KP, van Strijp JA. Chemotaxis inhibitory protein of *Staphylococcus aureus*, a bacterial antiinflammatory agent. *J Exp Med* 2004; 199(5):687-95.
- 20 Genestet C, Le Gouellec A, Chaker H, Polack B, Guery B, Toussaint B, Stasia MJ. Scavenging of reactive oxygen species by tryptophan metabolites helps *Pseudomonas aeruginosa* escape neutrophil killing. *Free Radic Biol Med* 2014; 73C:400-410.
- 21 Lappann M, Danhof S, Guenther F, Olivares-Florez S, Mordhorst IL, Vogel U. In vitro resistance mechanisms of *Neisseria meningitidis* against neutrophil extracellular traps. *Mol Microbiol* 2013; 89(3):433-49.

-
- 22 Malachowa N, Kobayashi SD, Freedman B, Dorward DW, DeLeo FR. Staphylococcus aureus leukotoxin GH promotes formation of neutrophil extracellular traps. *J Immunol* 2013; 191(12):6022-9.
- 23 Larrubia JR, Moreno-Cubero E, Lokhande MU, García-Garzón S, Lázaro A, Miquel J, Perna C, Sanz-de-Villalobos E. Adaptive immune response during hepatitis C virus infection *World J Gastroenterol* 2014; 20(13):3418-30.
- 24 Song H, Pavlicek JW, Cai F, Bhattacharya T, Li H, Iyer SS, Bar KJ, Decker JM, Goonetilleke N, Liu MK et al. Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. *Retrovirology* 2012; 9:89.
- 25 Vider-Shalit T, Sarid R, Maman K, Tsaban L, Levi R, Louzoun Y: Viruses selectively mutate their CD8+ T-cell epitopes—a large-scale immunomic analysis. *Bioinformatics* 2009; 25(12):i39-44.
- 26 Maman Y, Nir-Paz R, Louzoun Y. Bacteria modulate the CD8+ T cell epitope repertoire of host cytosol-exposed proteins to manipulate the host immune response. *PLoS Comput Biol* 2011; 7(10):e1002220.
- 27 Jawa V, Cousens LP, Awwad M, Wakshull E, Kropshofer H, De Groot AS. T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. *Clin Immunol* 2013; 149(3):534-55.
- 28 De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, Scott DW, Martin W. Activation of Natural Regulatory T cells by IgG Fc-derived Peptide “Tregitopes”. *Blood* 2008; 112(8):3303-11.

-
- 29 Cousens, LA, De Groot AS, Najafian, N., Martin WD. Tregitopes: An Immunomodulation Powerhouse, Human Immunology, Submitted.
- 30 De Groot AS, Cousens L, Mingozi F, Martin W. Tregitope peptides: the active pharmaceutical ingredient of IVIG? Clin Dev Immunol 2013; 2013:493138.
- 31 Moise L, Gutierrez AH, Bailey-Kellogg C, Terry F, Leng Q, Abdel Hady KM, Verberkmoes N, Sztejn MB, Losikoff P, Martin WD et al., Rothman A, De Groot AS. The two-faced T cell epitope: Examining the host-microbe interface with JanusMatrix. Hum Vaccin Immunother 2013; 9(7) 1577-86
- 32 Liu R, Moise L, Sangare K, Desrosiers J, Martin W, De Groot AS. Immunogenicity of T effector and Treg epitopes from H7N9 avian-origin influenza: impact of cross-reactivity with the human genome. J Immunol 2014; 192(1) Suppl: 72.12.
- 33 Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012; 3(7):610-20.
- 34 Losikoff PT, Terry F, Mishra S, Martin M, Ardito M, Bailey-Kellogg C, De Groot AS, Gregory SH. A hepatitis C virus-encoded epitope, homologous to a wide array of predicted human epitopes, stimulates a T-regulatory cell response in patients with chronic hepatitis C. Hepatology, Accepted (in proofs).
- 35 Li S, Floess S, Hamann A, Gaudieri S, Lucas A, Hellard M, Roberts S, Paukovic G, Plebanski M, Loveland BE et al. Analysis of FOXP3+ regulatory T cells that display apparent viral antigen specificity during chronic hepatitis C virus infection. PLoS Pathog 2009; 5(12):e1000707. Erratum in: PLoS Pathog 2012; 8(6).

-
- 36 Oldstone MB. Molecular mimicry, microbial infection, and autoimmune disease: evolution of the concept. *Curr Top Microbiol Immunol* 2005; 296:1-17.
- 37 Prestel J, Volkens P, Mentzer D, Lehmann HC, Hartung HP, Keller-Stanislawski B; for the GBS Study Group. Risk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany. *Pharmacoepidemiol Drug Saf* 2014. [Epub ahead of print] doi: 10.1002/pds.3638.
- 38 Li S, Jin T, Zhang HL, Yu H, Meng F, Concha Quezada H, Zhu J. Circulating Th17, Th22, and Th1 cells are elevated in the Guillain-Barré syndrome and downregulated by IVIg treatments. *Mediators Inflamm* 2014; 2014:740947.
- 39 Han F, Lin L, Warby SC, Faraco J, Li J, Dong SX, An P, Zhao L, Wang LH, Li QY et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. *Ann Neurol* 2011; 70(3):410-7.

1 **Figure Legends**

2

3 **Figure 1. Cross-conservation between T-cell receptor facing residues of T cell epitopes**
4 **may influence immune response.** Pathogens may exploit cross-conservation with self to reduce
5 immune recognition of pathogen epitopes. Cross-reactivity with the human microbiome has also
6 been observed. The sum or ratio of these influences may determine the phenotype of the
7 responding T cells. Understanding cross-conservation of the T cell epitope and its context is
8 critically important for understanding human immune responses to infection and vaccination.

9

10 **Figure 2. Cross-conservation between T-cell receptor facing residues of T cell epitopes**
11 **and the human genome may influence the response to influenza H7N9.** The virus may
12 exploit cross-conservation between its own epitopes with self epitopes (top). Unique epitopes
13 (middle) may be diminished, as has been demonstrated in our previous report. Cross-reactivity
14 with other influenza A strains may also be present (bottom), further modifying the immune
15 response. Each of these influences contributes to the final response to influenza infection or
16 vaccination, including seroconversion rates and antibody maturation and affinity.

17

18 **Figure 3. Putative Tolerizing T cell epitopes found in HIV.** Cytoscape can be used to illustrate
19 the relationship between a pathogen epitope and the human genome. In this figure the source
20 HIV Env peptide is represented as a green diamond, its constituent nine-mer epitopes as gray
21 squares, its cross-conserved partners in the human genome as blue triangles, and the source
22 human proteins as light purple circles. As shown in this figure, not only is the Env peptide highly
23 conserved in a number of different human proteins, but a single cross-conserved epitope can be
24 found in 32 alleles of the same human protein (source protein highlighted in orange).

25

Figure 1




Figure 2

